Trial Profile
A Pilot Study Targeting Angiogenesis Using Bevacizumab Combined With Chemotherapy and Histone Deacetylase Inhibitor (Valproic Acid) in Advanced Sarcomas
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Docetaxel (Primary) ; Gemcitabine (Primary) ; Valproic acid (Primary)
- Indications Sarcoma
- Focus Adverse reactions
- 22 Aug 2017 Status changed from active, no longer recruiting to completed.
- 02 Feb 2017 Planned primary completion date changed from 1 Jul 2016 to 1 Jul 2017.
- 10 May 2016 Status changed from recruiting to active, no longer recruiting.